Close Menu

TJ Johnson, John Lubniewski

Jan 18, 2019

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

More Like This

Jan 15, 2021

Broad Institute: Eric Lander, Todd Golub

Eric Lander, founding director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, has been named White House science advisor to President-elect Joseph Biden. He will specifically be nominated as director of the Office of Science and Technology Policy and serve as Presidential Science Advisor. The President-elect is designating the Presidential Science Advisor as a member of the Cabinet for the first time in history. Lander was a principal leader of the Human Genome Project, and during the Obama Administration he served as external co-chair of the President's Council of Advisors on Science and Technology.

Lander will step down from his roles at Broad, Harvard, and MIT and take an unpaid, academic leave of absence.

The Broad Institute's board has appointed Todd Golub, current chief scientific officer at the institute, as director. Golub is a founder and core member of the institute, and serves on its executive leadership team. He is also the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute and professor of pediatrics at Harvard Medical School. Golub joined the Dana-Farber and Harvard faculty in 1997, and served as a key scientific leader of the Whitehead Institute/MIT Center for Genome Research, the precursor organization of the Broad Institute. He has also been Howard Hughes Medical Institute investigator, and has served as chair of numerous scientific advisory boards, including St. Jude Children's Research Hospital and the National Cancer Institute's scientific advisory board.

Jan 15, 2021

Agilent Technologies: Allison Ballmer

Agilent Technologies has named Allison Ballmer as senior vice president of strategy and corporate development, reporting to President and CEO Mike McMullen.

Ballmer joined Agilent in May 2018 as vice president of business development and strategy for the company's Diagnostics and Genomics business. Prior to that, she worked for more than a decade at Roche. She is currently lead director of the board of directors at Mission Bio.

Jan 15, 2021

Exact Sciences: Andrew Slavitt

In a filing with the US Securities and Exchange Commission, Exact Sciences said that Andrew Slavitt submitted his resignation as a member of the company's board on Jan. 11 after having been been appointed by President-elect Joseph Biden as a White House Senior Advisor for COVID Response. 

Jan 14, 2021

Lunaphore Technologies: Paolo Ascierto, Jérôme Galon

Swiss life sciences company Lunaphore Technologies appointed Paolo Ascierto and Jérôme Galon, who are experts in immuno-oncology, to its new Scientific Advisory Board.

Ascierto is the director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Tumor Institute in Naples, Italy. He is a member of the Steering Committee of the Society of Melanoma Research and the board of directors of the Society of Immunotherapy of Cancer. He is also president of the Fondazione Melanoma Onlus and the Campania Society of ImmunoTherapy of Cancer.

Galon is the director of research at INSERM (the French National Institute of Health and Medical Research) and head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris. He is the cofounder of HalioDx and chairman of its scientific council.

Jan 13, 2021

C2i Genomics: Mark Oldroyd, Ravi Kandasamy, Alex Parker

C2i Genomics has appointed Mark Oldroyd as its chief business officer, Ravi Kandasamy as VP of research and development, and Alex Parker as a member of the firm's board of directors. 

Oldroyd previously served as senior VP at Tempus. Prior to Tempus, he was a senior director at Foundation Medicine.

Kandasamy most recently served as director of genomics at Bristol-Myers Squibb. In addition, he has previously served as manager of research and development in precision medicine at GlaxoSmithKline.

Parker currently serves as senior VP for clinical product strategy at Thrive Earlier Detection. Prior to Thrive, he spent more than seven years in leadership positions at Foundation Medicine. 

Jan 12, 2021

MeMed: Troy Boutelle

MeMed has appointed Troy Boutelle as VP of commercial, North America and GM, US. He will lead Haifa, Israel-based MeMed's operation in North America from Boston. He has 20 years of leadership experience at life science companies including at Eurofins-Viracor where he was its VP of sales of marketing prior to joining MeMed. He previously was commercial lead at Thermo Fisher Scientific where he led the commercial team for the Americas microbiology team.

Jan 08, 2021

Qiagen: Toraf Haag

Qiagen said Toraf Haag has been appointed to its supervisory board and audit committee. Since 2018 Haag has served as chairman of the management board of Germany-based global technology firm Voith. Before joining Voth in 2016 as chief financial officer, Haag served for more than 11 years as CFO and an executive committee member at Lonza Group.

Jan 06, 2021

DermTech: Ray Akhavan

DermTech has appointed Ray Akhavan as its general counsel. Most recently, Akhavan served as associate general counsel and chief intellectual property counsel at Ancestry. Prior to Ancestry, Akhavan served as general counsel and chief intellectual property counsel at Caris Life Sciences. He has also worked as a research biologist at the National Institutes of Health and as a patent examiner at the US Patent and Trademark Office. 

Jan 05, 2021

Novacyt: James McCarthy, Anthony Dyer

Clinical diagnostics firm Novacyt has appointed James McCarthy as its CFO and Anthony Dyer to a new role as its chief corporate development officer. McCarthy will become a board director, subject to shareholder approval at the company's annual general meeting. Dyer will remain a board director until then.

McCarthy has held senior positions in listed and private equity-backed businesses. He was CFO of Flint Group, and of Brambles' Europe, Middle East, and Africa-based Commonwealth Handling Equipment Pool (CHEP) business before being promoted to president of CHEP’s European team.

McCarthy trained as an accountant with Dairygold and has worked for Unilever and ICI, among other companies.

Jan 05, 2021

Biodesix: Ryan Siurek

Ryan Siurek has joined Biodesix as chief accounting officer. He was previously SVP, chief accounting officer and controller of Vail Resorts. Prior to that, he held various accounting and finance roles at Sprint, including VP controller and chief accounting officer, and VP, divisional CFO for the prepaid and wholesale and enterprise solutions divisions.

Jan 05, 2021

Exact Sciences: Mark Stenhouse, Pat Setji

Exact Sciences announced that Mark Stenhouse left his position as general manager of the company's screening business on Jan. 5. He will be succeeded by Pat Setji, Exact's vice president of business operations.

Over the last 20 years Setji has served in multiple sales and marketing leadership roles at Pfizer, Eli Lilly, and Exact. In connection with his departure, Stenhouse will assist with the transition as an advisor, and will remain with Exact as a non-executive employee through March 31.

Jan 05, 2021

SomaLogic: Jason Cleveland, Angela Bakker Lee, Tracy Hervey, David McGovern

SomaLogic this week announced several new executive appointments.

Jason Cleveland will be the company's new chief technology officer. He joined SomaLogic in 2015 as a consultant and became a principal research fellow in 2018. Prior to SomaLogic, he was cofounder, chairman, and CEO of Asylum Research, a manufacturer of atomic force microscopes (AFM). He began his career at Digital Instruments, an early AFM maker. Cleveland has a PHD in physics from the Universiy of California, Santa Barbara and is a fellow of the American Physical Society.

SomaLogic has also appointed Angela Bakker Lee as its executive VP for healthcare markets, Tracy Hervey as executive VP for life science markets, and David McGovern as senior VP of marketing.

Prior to SomaLogic, Bakker Lee most recently served as chief strategy officer at Quid, an AI text analytics platform provider. Bakker Lee also previously led IBM's Global Business Services Healthcare for North America. Prior to IBM, Bakker Lee spent 15 years with ZS Associates, a management consulting firm specializing in commercial strategy and sales and marketing operations. Before ZS Associates, she worked at Molecular Applications Group.

Hervey most recently served as chief commercial officer at Amplity Health. Prior to Amplity Health, she served as VP of global accounts at Icon. Before Icon, Hervey held sales leadership roles at data science firm Iqvia and PPD, a global contract research organization.

McGovern previously served as strategic payer marketing lead at Pfizer. Prior to Pfizer, McGovern served as VP of marketing and business development at Change Healthcare. Before Change Healthcare, he held various leadership roles in global commercial development, marketing, and market access at Johnson & Johnson, Merck, and Otsuka. McGovern has also served as VP of marketing at Nupathe, which was later sold to Teva Pharmaceuticals.

Jan 04, 2021

Color: Claire Vo, Emily Reuter, Ashley Chandler

Color has added three individuals to its upper management in connection with a $167 million Series D financing announced this week. Claire Vo will be Color's new chief product officer, having previously held the same title at Optimizely. Emily Reuter is Color's new vice president of strategy and operations, joining the company from Uber, where she was head of investor relations. Ashley Chandler has been named Color's vice president of marketing, and joins the company from Stripe, where she led several marketing functions through a period of rapid growth.

Dec 23, 2020

Diaceutics: Deborah Davis

Diaceutics, a data analytics and services provider for precision medicine, has appointed Deborah Davis as non-executive chair effective Jan. 4, 2021. Davis spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay; and technology companies Symantec and Verizon. She currently holds a number of non-executive director and board committee positions including with International Personal Finance, IDEX Biometrics, the Institute of Directors UK, and Which? Ltd.

Dec 22, 2020

Biological Dynamics: Kevin Han

Biological Dynamics, a company developing cancer early detection products, has named Kevin Han as chief financial officer. Previously, Han held positions in investor relations, corporate communications, and corporate sustainability strategies at Bio-Rad Laboratories. Prior to that, he was a portfolio manager for Lombard Odier Asset Management. Han started his career at Morgan Stanley and, later, Goldman Sachs, where he covered the medical technology and diagnostics sectors.